Tandem Diabetes Reports Smaller Loss, Beats Sales Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy TNDM?
Source: Benzinga
- Earnings Highlights: Tandem Diabetes reported a smaller-than-expected adjusted loss of one cent in Q4, significantly better than the consensus loss of eight cents, with sales rising 3% year-over-year to $290.4 million, surpassing the expected $277.03 million, indicating enhanced competitive strength in the market.
- Margin Improvement: The adjusted gross profit margin increased from 51% to 58%, and the adjusted operating profit of $8.3 million contrasts sharply with a loss of $30.2 million a year ago, showcasing significant progress in cost control and profitability.
- Future Guidance: The company forecasts fiscal 2026 sales between $1.065 billion and $1.085 billion, below the consensus of $1.103 billion; however, it remains committed to sustainable revenue growth through a pay-as-you-go model aimed at improving customer access.
- Market Performance: Tandem Diabetes shares surged 37.53% to $25.47, reflecting positive investor sentiment towards the company's performance, while technical analysis indicates strong short-term momentum, trading well above both the 20-day and 100-day simple moving averages.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNDM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNDM
Wall Street analysts forecast TNDM stock price to rise
18 Analyst Rating
8 Buy
10 Hold
0 Sell
Moderate Buy
Current: 18.520
Low
14.00
Averages
26.33
High
55.00
Current: 18.520
Low
14.00
Averages
26.33
High
55.00
About TNDM
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tandem Diabetes Reports Smaller Loss, Beats Sales Expectations
- Earnings Highlights: Tandem Diabetes reported a smaller-than-expected adjusted loss of one cent in Q4, significantly better than the consensus loss of eight cents, with sales rising 3% year-over-year to $290.4 million, surpassing the expected $277.03 million, indicating enhanced competitive strength in the market.
- Margin Improvement: The adjusted gross profit margin increased from 51% to 58%, and the adjusted operating profit of $8.3 million contrasts sharply with a loss of $30.2 million a year ago, showcasing significant progress in cost control and profitability.
- Future Guidance: The company forecasts fiscal 2026 sales between $1.065 billion and $1.085 billion, below the consensus of $1.103 billion; however, it remains committed to sustainable revenue growth through a pay-as-you-go model aimed at improving customer access.
- Market Performance: Tandem Diabetes shares surged 37.53% to $25.47, reflecting positive investor sentiment towards the company's performance, while technical analysis indicates strong short-term momentum, trading well above both the 20-day and 100-day simple moving averages.
See More
U.S. Stocks Rise, Nasdaq Gains Over 200 Points
- Nasdaq Performance: The Nasdaq Composite rose over 200 points on Friday, closing at 22,917.24, indicating strong demand for tech stocks and potentially reflecting investor optimism about future economic recovery.
- PPL Corporation Earnings: PPL Corporation reported mixed Q4 fiscal 2025 results with operating revenue of $2.27 billion, falling short of the $2.42 billion consensus estimate, although adjusted EPS of 41 cents met analyst expectations, highlighting challenges in revenue growth.
- Dividend Increase: PPL raised its quarterly dividend by 4.6% to 28.50 cents per share, demonstrating confidence in future cash flows and a commitment to shareholder returns amidst fluctuating earnings.
- Market Dynamics: On Friday, communication services stocks gained 2.3%, while healthcare stocks fell by 0.7%, indicating performance disparities across sectors that may influence investors' asset allocation strategies.
See More
Wall Street Analysts Adjust Outlook on YETI Stock
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on YETI stock, reflecting varying perspectives on the company's future performance, which could influence investor decisions and market sentiment.
- Overview of Ratings Updates: The adjustments include upgrades, downgrades, and initiations, indicating differing views among analysts regarding YETI's prospects, potentially leading to stock price volatility and impacting investor confidence.
- Market Reaction Expectations: The changes in analyst ratings may prompt a reevaluation of YETI stock in the market, necessitating investors to monitor these shifts to adjust their investment strategies and maintain an edge in a competitive landscape.
- Lack of Investment Advice: While the article provides information on rating changes, it does not offer specific investment advice, requiring investors to carefully consider analysts' opinions alongside market dynamics when making decisions.
See More
RingCentral Shares Surge After Strong Q4 Earnings and Guidance
- Strong Earnings Report: RingCentral reported Q4 earnings of $1.18 per share, surpassing the analyst consensus estimate of $1.14, indicating robust profitability and boosting market confidence in its future performance.
- Sales Beat Expectations: The company posted quarterly sales of $644.033 million, exceeding the analyst consensus of $643.509 million, reflecting its competitive position and sustained customer demand in the market.
- Significant Stock Surge: Following the positive earnings report, RingCentral's stock price jumped 37.3% to $40.35 during Friday's trading session, demonstrating investor optimism regarding the company's growth prospects.
- Shareholder Return Initiatives: The company not only raised its first-quarter guidance but also initiated a quarterly dividend and expanded its share buyback program, highlighting its commitment to shareholder returns and confidence in future cash flows.
See More
Tandem Diabetes Care Reports Record Q4 and Strategic Shift
- Sales Milestone: Tandem Diabetes achieved over $1 billion in global sales for 2025, with Q4 sales reaching $290 million, representing a 15% year-over-year growth, marking the company's second consecutive year of double-digit growth, indicating strong market demand and enhanced brand influence.
- Margin Improvement: In 2025, Tandem's gross margin increased to 54%, with Q4 gross margin hitting a historic high of 58%, demonstrating significant progress in cost control and operational efficiency, thereby strengthening the foundation for future profitability.
- Strategic Shift: The company announced the adoption of a pay-as-you-go reimbursement structure, which is expected to impact short-term sales but will significantly enhance the sustainability of its business model in the long term, reflecting Tandem's proactive response to market changes and forward-looking strategy.
- Future Outlook: U.S. sales for 2026 are projected to be between $730 million and $745 million, with pump shipment growth expected at 10% to 11% year-over-year, while international sales are anticipated to reach $335 million to $340 million, showcasing the company's expansion potential and growth confidence in global markets.
See More
Tandem Reports Record Q4 Revenue Amid Strategic Shift
- Revenue Beat: Tandem's Q4 revenue reached $290.4 million, exceeding market expectations of $277.2 million, marking the strongest quarter in the company's history and highlighting robust market demand and growth potential.
- Strategic Shift: The company guided for 2026 revenue between $1.065 billion and $1.085 billion, although below the consensus of $1.10 billion, this outlook reflects a strategic intent to transition to a pay-as-you-go model, aimed at improving patient access and revenue predictability.
- Margin Improvement: Tandem forecasts a gross margin of 56% to 57% and an adjusted EBITDA margin of 5% to 6% for 2026, indicating proactive efforts in optimizing cost structures and enhancing profitability.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment for TNDM is deemed 'extremely bullish' amid a 1,050% surge in message volume over 24 hours, reflecting strong investor confidence in the company's future growth potential.
See More
Tandem Diabetes Reports Smaller Loss, Beats Sales Expectations
- Earnings Highlights: Tandem Diabetes reported a smaller-than-expected adjusted loss of one cent in Q4, significantly better than the consensus loss of eight cents, with sales rising 3% year-over-year to $290.4 million, surpassing the expected $277.03 million, indicating enhanced competitive strength in the market.
- Margin Improvement: The adjusted gross profit margin increased from 51% to 58%, and the adjusted operating profit of $8.3 million contrasts sharply with a loss of $30.2 million a year ago, showcasing significant progress in cost control and profitability.
- Future Guidance: The company forecasts fiscal 2026 sales between $1.065 billion and $1.085 billion, below the consensus of $1.103 billion; however, it remains committed to sustainable revenue growth through a pay-as-you-go model aimed at improving customer access.
- Market Performance: Tandem Diabetes shares surged 37.53% to $25.47, reflecting positive investor sentiment towards the company's performance, while technical analysis indicates strong short-term momentum, trading well above both the 20-day and 100-day simple moving averages.
See More
U.S. Stocks Rise, Nasdaq Gains Over 200 Points
- Nasdaq Performance: The Nasdaq Composite rose over 200 points on Friday, closing at 22,917.24, indicating strong demand for tech stocks and potentially reflecting investor optimism about future economic recovery.
- PPL Corporation Earnings: PPL Corporation reported mixed Q4 fiscal 2025 results with operating revenue of $2.27 billion, falling short of the $2.42 billion consensus estimate, although adjusted EPS of 41 cents met analyst expectations, highlighting challenges in revenue growth.
- Dividend Increase: PPL raised its quarterly dividend by 4.6% to 28.50 cents per share, demonstrating confidence in future cash flows and a commitment to shareholder returns amidst fluctuating earnings.
- Market Dynamics: On Friday, communication services stocks gained 2.3%, while healthcare stocks fell by 0.7%, indicating performance disparities across sectors that may influence investors' asset allocation strategies.
See More
Wall Street Analysts Adjust Outlook on YETI Stock
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on YETI stock, reflecting varying perspectives on the company's future performance, which could influence investor decisions and market sentiment.
- Overview of Ratings Updates: The adjustments include upgrades, downgrades, and initiations, indicating differing views among analysts regarding YETI's prospects, potentially leading to stock price volatility and impacting investor confidence.
- Market Reaction Expectations: The changes in analyst ratings may prompt a reevaluation of YETI stock in the market, necessitating investors to monitor these shifts to adjust their investment strategies and maintain an edge in a competitive landscape.
- Lack of Investment Advice: While the article provides information on rating changes, it does not offer specific investment advice, requiring investors to carefully consider analysts' opinions alongside market dynamics when making decisions.
See More
RingCentral Shares Surge After Strong Q4 Earnings and Guidance
- Strong Earnings Report: RingCentral reported Q4 earnings of $1.18 per share, surpassing the analyst consensus estimate of $1.14, indicating robust profitability and boosting market confidence in its future performance.
- Sales Beat Expectations: The company posted quarterly sales of $644.033 million, exceeding the analyst consensus of $643.509 million, reflecting its competitive position and sustained customer demand in the market.
- Significant Stock Surge: Following the positive earnings report, RingCentral's stock price jumped 37.3% to $40.35 during Friday's trading session, demonstrating investor optimism regarding the company's growth prospects.
- Shareholder Return Initiatives: The company not only raised its first-quarter guidance but also initiated a quarterly dividend and expanded its share buyback program, highlighting its commitment to shareholder returns and confidence in future cash flows.
See More
Tandem Diabetes Care Reports Record Q4 and Strategic Shift
- Sales Milestone: Tandem Diabetes achieved over $1 billion in global sales for 2025, with Q4 sales reaching $290 million, representing a 15% year-over-year growth, marking the company's second consecutive year of double-digit growth, indicating strong market demand and enhanced brand influence.
- Margin Improvement: In 2025, Tandem's gross margin increased to 54%, with Q4 gross margin hitting a historic high of 58%, demonstrating significant progress in cost control and operational efficiency, thereby strengthening the foundation for future profitability.
- Strategic Shift: The company announced the adoption of a pay-as-you-go reimbursement structure, which is expected to impact short-term sales but will significantly enhance the sustainability of its business model in the long term, reflecting Tandem's proactive response to market changes and forward-looking strategy.
- Future Outlook: U.S. sales for 2026 are projected to be between $730 million and $745 million, with pump shipment growth expected at 10% to 11% year-over-year, while international sales are anticipated to reach $335 million to $340 million, showcasing the company's expansion potential and growth confidence in global markets.
See More
Tandem Reports Record Q4 Revenue Amid Strategic Shift
- Revenue Beat: Tandem's Q4 revenue reached $290.4 million, exceeding market expectations of $277.2 million, marking the strongest quarter in the company's history and highlighting robust market demand and growth potential.
- Strategic Shift: The company guided for 2026 revenue between $1.065 billion and $1.085 billion, although below the consensus of $1.10 billion, this outlook reflects a strategic intent to transition to a pay-as-you-go model, aimed at improving patient access and revenue predictability.
- Margin Improvement: Tandem forecasts a gross margin of 56% to 57% and an adjusted EBITDA margin of 5% to 6% for 2026, indicating proactive efforts in optimizing cost structures and enhancing profitability.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment for TNDM is deemed 'extremely bullish' amid a 1,050% surge in message volume over 24 hours, reflecting strong investor confidence in the company's future growth potential.
See More
